Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
interferon_beta-1a
|
| gptkbp:availableIn |
generic version
|
| gptkbp:brand |
gptkb:Rebif
|
| gptkbp:clinicalTrials |
Phase III trials
recommended_for_MS_treatment |
| gptkbp:contraindication |
depression
seizures liver enzyme elevation anaphylaxis thrombocytopenia severe liver disease hypersensitivity to interferon |
| gptkbp:date |
2002
|
| gptkbp:dosageForm |
pre-filled syringes
|
| gptkbp:firstAwarded |
for relapsing forms of multiple sclerosis
|
| gptkbp:gestationPeriod |
Category C
consult healthcare provider |
| gptkbp:hasPrograms |
patient assistance programs
|
| gptkbp:healthcare |
important for efficacy
injection technique side effects awareness importance of adherence |
| https://www.w3.org/2000/01/rdf-schema#label |
Rebif
|
| gptkbp:impact |
long-term therapy
|
| gptkbp:insuranceAccepted |
may require prior authorization
|
| gptkbp:interactsWith |
antidepressants
other immunosuppressants |
| gptkbp:is_monitored_by |
liver function tests
complete blood count |
| gptkbp:manufacturer |
Merck Serono
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:offers |
varies by region
|
| gptkbp:researchFocus |
combination therapies
quality of life improvements long-term safety improving delivery methods |
| gptkbp:route |
subcutaneous injection
|
| gptkbp:sideEffect |
fatigue
headache muscle pain injection site reactions flu-like symptoms |
| gptkbp:storage |
refrigerated
protected from light |
| gptkbp:triggerType |
modulates_immune_response
|
| gptkbp:usedFor |
multiple sclerosis
|